Medication: diabetes news
Approvals, new drugs and updates on treatments for type 1 and type 2 diabetes, from insulins to GLP-1 agonists and SGLT2 inhibitors.
Brazil approves five new semaglutide injectable medicines for type 2 diabetes
Brazil's health regulator Anvisa authorized five new semaglutide-based injectable medicines — Owozy, Seemasun, Zempneo, Semavy and Orsema — for type 2 diabetes and obesity, after Ozempic's patent expired in the country.
Read more →North Carolina preserves Medicaid coverage for obesity medications
The American Diabetes Association praised North Carolina's decision to preserve Medicaid coverage for FDA-approved obesity medications, which are also used to treat type 2 diabetes.
Read more →Mexico authorizes the first type 2 diabetes pill with dual approval for obesity
COFEPRIS authorized a new oral treatment from Eli Lilly that in phase 3 trials achieved reductions of up to 2.2 points of HbA1c and an average 12.4% body weight loss.
Read more →Orforglipron now has a brand name: Foundayz, Lilly's pill for type 2 diabetes
Eli Lilly's oral drug, already authorized in Mexico, showed in the ACHIEVE-3 trial a reduction of up to 2.2 points in HbA1c and an average 9.2% body weight loss over 52 weeks.
Read more →FDA approves Awiqli, the first weekly insulin for type 2 diabetes
Insulin icodec, marketed as Awiqli, becomes the first once-weekly basal insulin for adults with type 2 diabetes, with results comparable to daily insulins.
Read more →FDA approves bexagliflozin (Brenzavvy) for type 2 diabetes
This is a new sodium-glucose cotransporter 2 (SGLT2) inhibitor developed by TheracosBio to improve glycemic control.
Read more →Chile approves tirzepatide for type 2 diabetes and weight management
The Public Health Institute (ISP) authorized this Lilly drug, which acts on two hormonal mechanisms related to glucose and appetite.
Read more →CagriSema and orforglipron, 2026's most anticipated treatments
Novo Nordisk and Eli Lilly are advancing new combinations and an oral GLP-1 agonist for obesity and type 2 diabetes.
Read more →